Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.37 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19864354 | 0.85 | POLB (0.32) | POLB | |
| SCHEMBL19646435 | 0.79 | — | — | |
| SCHEMBL22858651 | 0.77 | POLB (0.30) | POLB | |
| SCHEMBL688493 | 0.74 | POLB (0.60) | POLBPIK3CDPER2CRY2P2RX7 | |
| SCHEMBL798077 | 0.73 | POLB (0.55) | POLBPIK3CDPER2CRY2P2RX7 | |
| SCHEMBL19863787 | 0.71 | — | — | |
| SCHEMBL3844844 | 0.70 | POLB (0.51) | POLBPIK3CDPER2CRY2P2RX7 | |
| SCHEMBL14370058 | 0.70 | POLB (0.59) | POLBPIK3CDPER2CRY2P2RX7 | |
| SCHEMBL17904507 | 0.68 | POLB (0.57) | POLBPIK3CDPER2P2RX7GRM5 | |
| SCHEMBL19481029 | 0.67 | POLB (0.56) | POLBPIK3CDPER2P2RX7GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329299-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329299-B2 | Heterocyclic compounds and uses thereof | PIK3CA, AKT1, AKT2 | POLB 1683/4885PIK3CD 6/4885PER2 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.